Revenue: As of FY2025 Q1, the actual value is USD 14.16 M, beating the estimate of USD 13.4 M.EPS: As of FY2025 Q1, the actual value is USD -2.32, missing the estimate of USD -0.155.EBIT: As of FY2025 Q1, the actual value is USD -26.43 M.<h3>Segment Revenue</h3><ul><li>Product Revenue: $10,918 thousand for the three months ended March 31, 2025, compared to $7,433 thousand for the same period in 2024, representing a 47% increase.</li><li>Lease Revenue: $1,884 thousand for the three months ended March 31, 2025, compared to $1,947 thousand for the same period in 2024, representing a 3% decrease.</li><li>Service Revenue: $1,357 thousand for the three months ended March 31, 2025, compared to $1,208 thousand for the same period in 2024, representing a 12% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $27,345 thousand for the three months ended March 31, 2025, compared to - $2,157 thousand for the same period in 2024.</li><li>Operating Loss: - $5,790 thousand for the three months ended March 31, 2025, compared to - $2,850 thousand for the same period in 2024.</li><li>Total Operating Expenses: $12,915 thousand for the three months ended March 31, 2025, compared to $8,514 thousand for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $6,938 thousand for the three months ended March 31, 2025, compared to - $5,307 thousand for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $531 thousand for the three months ended March 31, 2025, compared to - $1,226 thousand for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $9,691 thousand for the three months ended March 31, 2025, compared to - $130 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Change in Fair Value of Warrant Liabilities: - $21,714 thousand for the three months ended March 31, 2025, compared to $495 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on continuous innovation and has launched its proprietary next-generation ALLY System, which is designed to transform premium cataract surgery by utilizing advanced robotic technologies.</li><li>Proposed Acquisition by Alcon: LENSAR, Inc. entered into a Merger Agreement with Alcon Research, LLC, which is expected to close in mid-to-late 2025, subject to customary closing conditions, including approval by stockholders and regulatory approvals.</li></ul>

Lensar - W/I | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 14.16 M